Acacia's PONV therapy passes latest Phase III test

Acacia Pharma Group plc (Cambridge, U.K.) said Baremsis IV amisulpride (formerly APD421) met the primary endpoint in a Phase III study to treat postoperative nausea and vomiting (PONV). Compared with placebo, both Baremsis doses led to a significantly greater complete response rate, defined as resolution of the PONV episode with no recurrence of vomiting or requirement for further antiemetic rescue in the 24-hour period after treatment (p<0.025).

The company said it plans to publish detailed data from the 568-patient study and present them at scientific meetings. ...